Dr. Daniel S. von Hoff Joins IMMUNIC Board
Ticker: IMUX · Form: 8-K · Filed: Dec 18, 2024 · CIK: 1280776
| Field | Detail |
|---|---|
| Company | Immunic, INC. (IMUX) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $610,000, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, management-change
TL;DR
IMMUNIC adds oncology guru Dr. Daniel S. von Hoff to its board.
AI Summary
On December 13, 2024, IMMUNIC, INC. filed an 8-K report detailing the election of Dr. Daniel S. von Hoff as a Class II director, effective immediately. Dr. von Hoff brings extensive experience in oncology drug development and clinical trials to the IMMUNIC board.
Why It Matters
The addition of a seasoned oncology expert like Dr. von Hoff could bolster IMMUNIC's strategic direction and clinical development efforts, particularly in its focus areas.
Risk Assessment
Risk Level: low — This filing primarily concerns a board appointment and does not involve significant financial transactions or operational changes.
Key Players & Entities
- IMMUNIC, INC. (company) — Registrant
- Dr. Daniel S. von Hoff (person) — Newly elected Class II director
- December 13, 2024 (date) — Date of earliest event reported
FAQ
Who was elected as a new director for IMMUNIC, INC.?
Dr. Daniel S. von Hoff was elected as a Class II director.
When was the election of the new director effective?
The election was effective immediately as of December 13, 2024.
What is Dr. Daniel S. von Hoff's area of expertise?
Dr. von Hoff has extensive experience in oncology drug development and clinical trials.
What class of director was Dr. Daniel S. von Hoff elected as?
Dr. Daniel S. von Hoff was elected as a Class II director.
What is the principal executive office address for IMMUNIC, INC.?
The principal executive offices are located at 1200 Avenue of the Americas, Suite 200, New York, NY 10036.
Filing Stats: 891 words · 4 min read · ~3 pages · Grade level 10.3 · Accepted 2024-12-18 16:36:12
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC In
- $610,000 — for Dr. Vitt's current annual salary of $610,000 and annual target bonus of 55% of Dr. V
- $100,000 — ny may reimburse Dr. Vitt in respect of $100,000 of housing expenses in the United State
Filing Documents
- e664091_8k-immunic.htm (8-K) — 24KB
- e664091_ex10-1.htm (EX-10.1) — 97KB
- e664091_ex10-2.pdf (8-K) — 267KB
- image1.jpg (GRAPHIC) — 6KB
- image2.jpg (GRAPHIC) — 4KB
- 0001193805-24-001496.txt ( ) — 1054KB
- imux-20241213.xsd (EX-101.SCH) — 3KB
- imux-20241213_lab.xml (EX-101.LAB) — 33KB
- imux-20241213_pre.xml (EX-101.PRE) — 22KB
- e664091_8k-immunic_htm.xml (XML) — 4KB
02. Departure of Directors or Principal Officers; Election
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 13, 2024, in connection with Dr. Vitt's planned temporary relocation to the United States, Dr. Daniel Vitt, Chief Executive Officer and Director of Immunic, Inc. (the "Company"), entered into an employment agreement with the Company setting forth terms and conditions regarding Dr. Vitt's renumeration and other provisions of employment with the Company during his relocation to the United States (the "New Employment Agreement"). During such period of time, Dr. Vitt's service on the management board of Immunic AG, a wholly owned subsidiary of the Company (the "Management Board"), will be paused until the end of the temporary relocation period. The New Employment Agreement provides that Dr. Vitt will continue to serve as Chief Executive Officer until the earlier of the date that Dr. Vitt is reappointed to the Management Board and Dr. Vitt's Date of Termination (as defined in the New Employment Agreement). Dr. Vitt will continue to dedicate substantially all his time to the affairs of the Company. The New Employment Agreement provides for Dr. Vitt's current annual salary of $610,000 and annual target bonus of 55% of Dr. Vitt's annual salary. From time to time, Dr. Vitt may continue to receive equity incentive awards pursuant to the Company's 2019 Omnibus Equity Incentive Plan Equity Plan (or supplemental or succeeding equity plan as applicable). Certain compensation received by Dr. Vitt, whether in concordance with the New Employment Agreement or otherwise, is subject to the Company's clawback compensation policy (and any other similar policy as applicable). Under the New Employment Agreement, Dr. Vitt is entitled to participate in employee benefit plans of the Company. Additionally, on a monthly basis and subject to certain conditions, the Company may reimburse Dr. Vitt in respect of $100,000 of
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description of Exhibit 10.1 Employment Agreement, dated December 13, 2024, between Immunic, Inc. and Dr. Daniel Vitt. 10.2 Agreement on the Suspension of the Service Agreement, dated December 18, 2024, between Immunic AG and Dr. Daniel Vitt.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: December 18, 2024 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer